Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus OGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus OGEN.
ESTRADIOL VALERATE AND DIENOGEST vs OGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen that binds to estrogen receptors (ERα and ERβ) to regulate gene transcription, promoting endometrial growth and suppressing gonadotropins. Dienogest is a progestin with partial antiandrogenic activity, binding to progesterone receptors to inhibit endometrial proliferation and ovulation, and reducing androgen synthesis.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription leading to cell proliferation and differentiation in target tissues.
One tablet (2 mg estradiol valerate and 3 mg dienogest) once daily orally, without interruption, following the first day of menstrual cycle.
0.75 mg orally once daily, cyclically (3 weeks on, 1 week off) for moderate to severe vasomotor symptoms associated with menopause.
None Documented
None Documented
Estradiol valerate: Terminal half-life of estradiol is 13-15 hours; valerate ester is rapidly hydrolyzed, so systemic estradiol half-life applies. Dienogest: Terminal half-life ~8-10 hours, increasing to ~12-14 hours with multiple dosing due to competitive inhibition of CYP3A4.
Terminal elimination half-life of estrone is approximately 10-24 hours (mean ~14 hours); clinical context: permits once-daily dosing.
Estradiol valerate: Renal (primarily as glucuronide and sulfate conjugates) ~40%, Fecal ~60%. Dienogest: Renal ~60% (mostly unchanged), Fecal ~30%.
Renal elimination of conjugated metabolites (estrone sulfate, estradiol glucuronide) accounts for >95% of excretion; fecal elimination is <5%.
Category D/X
Category C
Estrogen
Estrogen